Management of neuromyelitis optica spectrum disorder at the Escuela Hospital, Honduras
DOI:
https://doi.org/10.56294/saludcyt20251542Keywords:
Neuromyelitis Optica, Central Nervous System, RituximabAbstract
Neuromyelitis optica spectrum disorder is an autoimmune-based nosological entity with inflammatory characteristics that affects the central nervous system: optic nerves, spinal cord and brainstem. Objective: To present a series of clinical cases to briefly review the management of neuromyelitis optica spectrum disorder. Methodology: A retrospective and descriptive analysis was performed on the patients who attended the outpatient clinic of the Teaching Hospital and who have been diagnosed and followed up for neuromyelitis optica spectrum disorder over the last 20 years. Results: Eight patients (100.0%) were female, ranging in age from 19 to 45 years, with a mean of 32 years. All patients (8) (100.0%) underwent anti-aquapurin 4 antibodies for diagnosis; four (50.0%) had unremarkable brain and orbital magnetic resonance imaging (MRI). Neuromyelitis optica spectrum disorder is a disease that requires an accurate diagnosis based on clinical features, anti-aquapurin 4 antibodies, and imaging studies. Treatment may begin with steroids, although in cases where the disease is not controlled, rituximab may be used.
References
1. Jarius S, Paul F, Weinshenker BG, Levy M, Kim HJ, Wildemann B. Neuromyelitis optica. Nature Reviews. Disease Primers [Internet]. 2020 [consultado el 10 de mayo 2025]; 6(1):85. Doi: 10.1038/s41572-020-0214-9
2. Kümpfel T, Giglhuber K, Aktas O, Ayzenberg I, Bellmann-Strobl J, Häußler V, Havla J, Hellwig K, Hümmert MW, Jarius S, Kleiter I, Klotz L, Krumbholz M, Paul F, Ringelstein M, Ruprecht K, Senel M, Stellmann JP, Bergh FT, Trebst C, Tumani H, Warnke C, Wildemann B, Berthele A; Neuromyelitis Optica Study Group (NEMOS). Update on the diagnosis and treatment of neuromyelitis optica spectrum disorders (NMOSD) - revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part II: Attack therapy and long-term management. J Neurol. 2024 Jan;271(1):141-176. doi: 10.1007/s00415-023-11910-z. Erratum in: J Neurol. 2024 Jun;271(6):3702-3707. https://doi.org/10.1007/s00415-023-11910-z
3. Costello F. Neuromyelitis optica spectrum disorders. Continuum [Internet]. 2022 [consultado el 10 de mayo 2025]; 28(4):1131–1170. Doi: 10.1212/CON.0000000000001168
4. Holroyd KB, Manzano GS, Levy M. Update on neuromyelitis optica spectrum disorder. Curr Opin Ophthalmol. 2020 Nov;31(6):462-468. https://doi.org/10.1097/icu.0000000000000703
5. Filippi M, Preziosa P, Margoni M, Rocca MA. Diagnostic Criteria for Multiple Sclerosis, Neuromyelitis Optica Spectrum Disorders, and Myelin Oligodendrocyte Glycoprotein-immunoglobulin G-associated Disease. Neuroimaging Clin N Am. 2024 Aug;34(3):293-316. https://doi.org/10.1016/j.nic.2024.03.001
6. Anderson M, Levy M. Advances in the long-term treatment of neuromyelitis optica spectrum disorder. Journal of Central Nervous System Disease [Internet]. 2024 [consultado el 10 de mayo 2025]; 16. Doi:10.1177/11795735241231094
7. Papp V, Magyari M, Aktas O, Berger T, Broadley SA, Cabre P, Jacob A, Kira JI, Leite MI, Marignier R, Miyamoto K, Palace J, Saiz A, Sepulveda M, Sveinsson O, Illes Z. Worldwide Incidence and Prevalence of Neuromyelitis Optica: A Systematic Review. Neurology. 2021 Jan 12;96(2):59-77. https://doi.org/10.1212/wnl.0000000000011153
8. Arnett S, Chew SH, Leitner U, Hor JY, Paul F, Yeaman MR, et al. Sex ratio and age of onset in AQP4 antibody-associated NMOSD: a review and meta-analysis. J Neurol [Internet]. 2024 [consultado el 10 de mayo 2025]; 271(8):4794-4812. https://doi.org/10.1007/s00415-024-12452-8
9. Wang Y, Fu J, Song H, Xu Q, Zhou H, Wei S. Differences in the involved sites among different types of demyelinating optic neuritis in traditional MRI examination: A systematic review and meta-analysis. Adv Ophthalmol Pract Res [Internet]. 2021 [consultado el 10 de mayo 2025]; 1(2):100019. https://doi.org/10.1016/j.aopr.2021.100019
10. Yin Z, Qiu Y, Duan A, Fang T, Chen Z, Wu J, et al. Different monoclonal antibodies and Yin Z, Qiu Y, Duan A, Fang T, Chen Z, Wu J, Wang Z, Chen G. Different monoclonal antibodies and immunosuppressants administration in patients with neuromyelitis optica spectrum disorder: a Bayesian network meta-analysis. J Neurol. 2023 Jun;270(6):2950-2963. https://doi.org/10.1007/s00415-023-11641-1.
Published
Issue
Section
License
Copyright (c) 2025 Dulce Escalante , Gabriel Isaias Lagos, Harlis Estrada Pastrana , Pablo Carías, Alejandro Carías , Jhossmar Cristians Auza-Santivañez , Freddy Ednildon Bautista-Vanegas, Dilma Villca-Villca (Author)
This work is licensed under a Creative Commons Attribution 4.0 International License.
The article is distributed under the Creative Commons Attribution 4.0 License. Unless otherwise stated, associated published material is distributed under the same licence.
